Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

United Therapeutic 1000 SPRING ST SILVER SPRING MD 20910 USA

www.unither.com P: 301-608-9292 F: 301-608-9291

Description:

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.

Key Statistics

Overview:

Market Capitalization, $K 15,303,704
Enterprise Value, $K 14,796,004
Shares Outstanding, K 44,356
Annual Sales, $ 2,328 M
Annual Net Income, $ 984,800 K
Last Quarter Sales, $ 714,900 K
Last Quarter Net Income, $ 278,100 K
EBIT, $ 1,263 M
EBITDA, $ 1,317 M
60-Month Beta 0.57
% of Insider Shareholders 12.50%
% of Institutional Shareholders 94.08%
Float, K 38,811
% Float 87.50%
Short Volume Ratio 0.81

Growth:

1-Year Return 57.53%
3-Year Return 75.60%
5-Year Return 323.79%
5-Year Revenue Growth 42.98%
5-Year Earnings Growth 47.95%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 5.85 on 07/31/24
Next Earnings Date 11/06/24
Earnings Per Share ttm 21.76
EPS Growth vs. Prev Qtr -5.19%
EPS Growth vs. Prev Year 11.64%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 09/23/09

UTHR Ratios

Ratio
Price/Earnings ttm 15.85
Price/Earnings forward 13.64
Price/Earnings to Growth 1.23
Return-on-Equity % 18.82%
Return-on-Assets % 15.61%
Profit Margin % 42.31%
Debt/Equity 0.09
Price/Sales 6.59
Price/Cash Flow 15.35
Price/Book 2.65
Book Value/Share 128.06
Interest Coverage 22.49
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar